Targeted delivery of heparin and LMWH using a fibrin antibody prevents restenosis

Atherosclerosis

Volumn 176, Issue 1, 2004, Pages 73-81

  Thomas, Anita C ^a,b   Campbell, Julie H ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

Anti restenotic drug; Experimental model; Heparin; Targeted drug delivery

Indexed keywords

FIBRIN ANTIBODY; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERY INJURY; ARTERY WALL; ARTICLE; BALLOON CATHETER; CAROTID ARTERY; CELL COUNT; CONTROLLED STUDY; CROSS LINKING; DRUG DELIVERY SYSTEM; EXTRACELLULAR MATRIX; INTIMA; LOW DRUG DOSE; NONHUMAN; PRIORITY JOURNAL; RESTENOSIS;

ANIMALS; ANTIBODIES; ANTICOAGULANTS; CAROTID ARTERIES; CAROTID STENOSIS; CROSS-LINKING REAGENTS; DISEASE MODELS, ANIMAL; DRUG DELIVERY SYSTEMS; FIBRIN; HEPARIN, LOW-MOLECULAR-WEIGHT; RABBITS; RECURRENCE; STENTS; THROMBOSIS; TUNICA INTIMA;

EID: 4043177078     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2004.05.006     Document Type: Article

References (36)

1. Meneveau N., Schiele F., Grollier G., et al. Local delivery of nadroparin for the prevention of neointimal hyperplasia following stent implantation: results of the IMPRESS trial. Eur. Heart J. 21:2000;1767-1775
2. Bennett M.R., O'Sullivan M. Mechanisms of angioplasty and stent restenosis: implication for design of rational therapy. Pharmacol. Ther. 91:2001;149-166
3. Sousa J.E., Serruys P.W., Costa M.A. New frontiers in cardiology. Drug-eluting stents: Part 1. Circulation. 107:2003;2274-2279
4. Gertz S.D., Barry W.L., Gimple L.W., et al. Predictors of luminal narrowing by neointima after angioplasty in atherosclerotic rabbits. Cardiovasc. Res. 36:1997;396-407
5. Ahn U.K., Jeong M.H., Kim J.W., et al. Preventive effects of the heparin-coated stent on restenosis in the porcine model. Cathete. Cardiovasc. Interv. 48:1999;324-330
6. Kornowski R., Hong M.K., Tio R.O., et al. In-stent restenosis: contributions of inflammatory responses and arterial injury to neointimal hyperplasia. J. Am. Coll. Cardiol. 31:1998;224-230
7. Edelman E.R., Karnovsky M.J. Contrasting effects of the intermittent and continuous administration of heparin in experimental restenosis. Circulation. 89:1994;770-776
8. Faxon D.P., Spiro T.E., Minor S., et al. Low molecular weight heparin in prevention of restenosis after angioplasty. Results of enoxaparin restenosis (ERA) trial. Circulation. 90:1994;908-914
9. Lovich M.A., Edelman E.R. Tissue concentration of heparin, not administered dose, correlates with the biological response of injured arteries in vivo. Proc. Natl. Acad. Sci. U.S.A. 96:1999;11111-11116
10. Rogers C., Karnovsky M.J., Edelman E.R. Inhibition of experimental neointimal hyperplasia and thrombosis depends on the type of vascular injury and the site of drug administration. Circulation. 88:1993;1215-1221
11. Matsumoto Y., Shimokawa H., Morishige K., Eto Y., Takeshita A. Reduction in neointimal formation with a stent coated with multiple layers of releasable heparin in porcine coronary arteries. J. Cardiovasc. Pharmacol. 39:2002;513-522
12. Schwartz R.S., Edelman E.R., Carter A., et al. Drug-eluting stents in preclinical studies. Recommended evaluation from a consensus group. Circulation. 106:2002;1867-1873
13. Thomas A.C., Campbell J.H. Timecourse of fibrin deposition and removal after arterial injury. Thromb. Res. 109:2003;65-69
14. Hanke H., Oberhoff M., Hanke S., et al. Inhibition of cellular proliferation after experimental balloon angioplasty by low-molecular-weight heparin. Circulation. 85:1992;1548-1556
15. Serruys P.W., van Hout B., Bonnier H., et al. Randomised comparison of implantation of heparin-coated stents with balloon angioplasty in selected patients with coronary artery disease (Benestent II). Lancet. 352:1998;673-681
16. Vrolix M.C.M., Legrand V.M., Reiber J.H.C., et al. Heparin-coated Wiktor stents in human coronary arteries (MENTOR trial). Am. J. Cardiol. 86:2000;385-389
17. Dewerchin M., Lijnen H.R., Van Hoef B., De Cock F., Collen D. Biochemical properties of conjugates of urokinase-type plasminogen activator with a monoclonal antibody specific for cross-linked fibrin. Eur. J. Biochem. 185:1989;141-149
18. Schachtschabel U., Pavlinkova G., Lou D., Kohler H. Antibody-mediated gene delivery for B-cell lymphoma in vitro. Cancer Gene Ther. 3:1996;365-372
19. Brekke O.H., Sandlie I. Therapeutic antibodies for human diseases at the dawn of the twenty-first century. Nat. Rev. Drug Discov. 2:2003;52-62
20. Thomas A.C., Campbell J.H. Differences in response of rat and rabbit arteries to injury. Biomed. Res. 11:2000;189-196
21. Gimple L.W., Gertz S.D., Haber H.L., et al. Effect of chronic subcutaneous or intramural administration of heparin on femoral artery restenosis after balloon angioplasty in hypercholesterolemic rabbits. Circulation. 86:1992;1536-1546
22. Bingley J.A., Hayward I.P., Campbell J.H., Campbell G.R. Arterial heparin sulfate proteoglycans inhibit vascular smooth muscle cell proliferation and phenotype change in vitro and neointimal formation in vivo. J. Vasc. Surg. 28:1998;308-318
23. Currier J.W., Pow T.K., Haudenschild C.C., Minihan A., Faxon D.P. Low molecular weight heparin (enoxaparin) reduces restenosis after iliac angioplasty in the hypercholesterolemic rabbit. J. Am. Coll. Cardiol. 17:1991;118B-125B
24. Larm O., Larsson R., Olsson P. A new non-thrombogenic surface prepared by selective covalent binding of heparin via a modified reducing terminal residue. Biomater. Med. Dev. Art. Org. 11:1983;161-173
25. Liang J.F., Li Y.T., Yang V.C. A novel approach for delivery of enzyme drugs: preliminary demonstration of feasibility and utility in vitro. Int. J. Pharm. 202:2000;11-20
26. Chandrasekhar S., Esterman M.A., Hoffman H.A. Microdetermination of proteoglycans and glycosaminoglycans in the presence of guanidine hydrochloride. Anal. Biochem. 161:1987;103-108
27. Sasseen B.M., Gray B.D., Gal D., et al. Local delivery of a hydrophobic heparin reduces neointimal hyperplasia after balloon injury in rat carotid but not pig coronary arteries. J. Cardiovasc. Pharmacol. Therapeut. 6:2001;377-383
28. Miller A.L., Plane F., Jeremy J.Y., McKinnon H.J., Jackson C.L. Delayed recovery of receptor-mediated functional responses to acetylcholine in mouse isolated carotid arteries following endothelial denudation in vivo. J. Vasc. Res. 40:2003;449-459
29. Joseph P.A.M., Garg H.G., Thompson B.T., Liu X., Hales C.A. Influence of molecular weight, protein core and charge of native heparin fractions on pulmonary artery smooth muscle cell proliferation. Biochem. Biophys. Res. Comm. 241:1997;18-23
30. Carlsson J., Drevin H., Axén R. Protein thiolation and reversible protein-protein conjugation. Biochem. J. 173:1978;723-737
31. Heimgartner U., Kozulic B., Mosbach K. Reversible and irreversible cross-linking of immunoglobulin heavy chains through their carbohydrate residues. Biochem. J. 267:1990;585-591
32. Bertrand O.F., Sipehia R., Mongrain R., et al. Biocompatibility aspects of new stent technology. J. Am. Coll. Cardiol. 32:1998;562-571
33. Kiesz R.S., Buszman P., Martin J.L., et al. Local delivery of enoxaparin to decrease restenosis after stenting: results of initial multicenter trial. Circulation. 103:2001;26-31
34. Newby A.C., Zaltsman A.B. Molecular mechanisms in intimal hyperplasia. J. Pathol. 190:2000;300-309
35. Gorodetsky R., Vexler A., Shamir M., et al. New cell attachment peptide sequences from conserved epitopes in the carboxy termini of fibrinogen. Exp. Cell Res. 287:2003;116-129
36. Thomas AC, Campbell JH. Conjugation of an anti-fibrin antibody for targeted delivery of anti-restenotic drugs. J Control Release. Submitted for publication.